Identification of β-amyloid species in canine cerebrospinal fluid by mass spectrometry

Neurobiology of Aging

Volumn 34, Issue 9, 2013, Pages 2125-2132

  Sarasa, Leticia ^a   Allué, José Antonio ^a   Pesini, Pedro ^a   González Martínez, Ángela ^c   Sarasa, Manuel ^a,b  

^a Araclon Biotech Ltd   (Spain)

^b UNIVERSITY OF ZARAGOZA   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Alzheimer's disease; Amyloid beta peptides; Canine model; Cerebrospinal fluid; Immunoprecipitation; MALDI TOF

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-13]; AMYLOID BETA PROTEIN[1-14]; AMYLOID BETA PROTEIN[1-18]; AMYLOID BETA PROTEIN[1-33]; AMYLOID BETA PROTEIN[1-34]; AMYLOID BETA PROTEIN[1-37]; AMYLOID BETA PROTEIN[1-38]; AMYLOID BETA PROTEIN[1-39]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE; GAMMA SECRETASE; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEGRADATION; HUMAN; IMMUNOPRECIPITATION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; SIGNAL TRANSDUCTION; SPECIES IDENTIFICATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; DOGS; HUMANS; MASS SPECTROMETRY;

EID: 84878952969     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2013.03.009     Document Type: Article

References (49)

1. Bernedo V., Insua D., Suarez M.L., Santamarina G., Sarasa M., Pesini P. Beta-amyloid cortical deposits are accompanied by the loss of serotonergic neurons in the dog. J.Comp Neurol. 2009, 513:417-429.
2. Bibl M., Esselmann H., Otto M., Lewczuk P., Cepek L., Ruther E., Kornhuber J., Wiltfang J. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides. Electrophoresis 2004, 25:2912-2918.
3. Bibl M., Mollenhauer B., Lewczuk P., Esselmann H., Wolf S., Trenkwalder C., Otto M., Stiens G., Ruther E., Kornhuber J., Wiltfang J. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias. Mol. Psychiatry 2007, 12:671-680.
4. Blasko I., Jellinger K., Kemmler G., Krampla W., Jungwirth S., Wichart I., Tragl K.H., Fischer P. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Neurobiol. Aging 2008, 29:1-11.
5. Blennow K., Hampel H., Weiner M., Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 2010, 6:131-144.
6. Cole R.B. Some tenets pertaining to electrospray ionization mass spectrometry. J.Mass Spectrom. 2000, 35:763-772.
7. Colle M., Hauw J., Crespeau F., Uchihara T., Akiyama H., Checler F., Pageat P., Duykaerts C. Vascular and parenchymal Abeta deposition in the aging dog: correlation with behavior. Neurobiol. Aging 2000, 21:695-704.
8. Conboy J.J., Wood K.G., Lame M.E., Durham R.A., Geoghegan K.F. Modification of amyloid-beta (1-40) by a protease inhibitor creates risk of error in mass spectrometric quantitation of amyloid-beta (1-42). Anal. Biochem. 2008, 382:147-149.
9. Cosentino S.A., Stern Y., Sokolov E., Scarmeas N., Manly J.J., Tang M.X., Schupf N., Mayeux R.P. Plasma [beta]-amyloid and cognitive decline. Arch. Neurol. 2010, 67:1485-1490.
10. Cummings B.J., Head E., Ruehl W., Milgram N.W., Cotman C.W. The canine as an animal model of human aging and dementia. Neurobiol. Aging 1996, 17:259-268.
11. Du P., Wood K.M., Rosner M.H., Cunningham D., Tate B., Geoghegan K.F. Dominance of amyloid precursor protein sequence over host cell secretases in determining beta-amyloid profiles studies of interspecies variation and drug action by internally standardized immunoprecipitation/mass spectrometry. J.Pharmacol. Exp. Ther. 2007, 320:1144-1152.
12. Eckman E.A., Eckman C.B. Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem. Soc. Trans. 2005, 33:1101-1105.
13. Fenn J.B. Ion formation from charged droplets: roles of geometry, energy, and time. J.Am. Soc. Mass Spectrom. 1993, 4:524-535.
14. Fenn J.B., Mann M., Meng C.K., Wong S.F., Whitehouse C.M. Electrospray ionization for mass spectrometry of large biomolecules. Science 1989, 246:64-71.
15. Fernandez de la Mora J. Electrospray ionization of large multiply charged species proceeds via Dole's charged residue mechanism. Anal. Chim. Acta 2000, 406:93-104.
16. Frisoni G.B., Fox N.C., Jack C.R., Scheltens P., Thompson P.M. The clinical use of structural MRI in Alzheimer disease. Nat. Rev. Neurol. 2010, 6:67-77.
17. Glückmann M., Karas M. The initial ion velocity and its dependence on matrix, analyte and preparation method in ultraviolet matrix-assisted laser desorption/ionization. J.Mass Spectrom. 1999, 34:467-477.
18. Glückmann M., Pfenninger A., Krüger R., Thierolf M., Karas M., Horneffer V., Hillenkamp F., Strupat K. Mechanisms in MALDI analysis: surface interaction or incorporation of analytes?. Int. J. Mass Spectrom. 2001, 210-211. 121-132.
19. González-Martínez A., Rosado B., Pesini P., Suárez M.L., Santamarina G., García-Belenguer S., Villegas A., Monleón I., Sarasa M. Plasma beta-amyloid peptides in canine aging and cognitive dysfunction as a model of Alzheimer's disease. Exp. Gerontol. 2011, 46:590-596.
20. Greg T Hermanson. Bioconjugate Techniques. Second ed.Academic Press, San Diego, CA, 2010.
21. Gunn A.P., Masters C.L., Cherny R.A. Pyroglutamate-Abeta: role in the natural history of Alzheimer's disease. Int. J. Biochem. Cell Biol. 2010, 42:1915-1918.
22. Haass C. Take five-BACE and the γ-secretase quartet conduct Alzheimer's amyloid β-peptide generation. EMBO J. 2004, 23:483-488.
23. Head E., McCleary R., Hahn F.F., Milgram N.W., Cotman C.W. Region-specific age at onset of beta-amyloid in dogs. Neurobiol. Aging 2000, 21:89-96.
24. Huse J.T., Liu K., Pijak D.S., Carlin D., Lee V.M., Doms R.W. Beta-secretase processing in the trans-Golgi network preferentially generates truncated amyloid species that accumulate in Alzheimer's disease brain. J.Biol. Chem. 2002, 277:16278-16284.
25. Ijsselstijn L., Dekker L.J., Koudstaal P.J., Hofman A., Sillevis Smitt P.A., Breteler M.M., Luider T.M. Serum clusterin levels are not increased in presymptomatic Alzheimer's disease. J.Proteome. Res. 2011, 10:2006-2010.
26. Insua D., Suarez M.L., Santamarina G., Sarasa M., Pesini P. Dogs with canine counterpart of Alzheimer's disease lose noradrenergic neurons. Neurobiol. Aging 2010, 31:625-635.
27. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010, 9:119-128.
28. Karas M., Bachmann D., Hillenkamp F. Influence of the wavelength in high-irradiance ultraviolet laser desorption mass spectrometry of organic molecules. Anal. Chem. 1985, 57:2935-2939.
29. Karas M., Gluckmann M., Schafer J. Ionization in matrix-assisted laser desorption/ionization: singly charged molecular ions are the lucky survivors. J.Mass Spectrom. 2000, 35:1-12.
30. Karas M., Hillenkamp F. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons. Anal. Chem. 1988, 60:2299-2301.
31. Karas M., Krüger R. Ion formation in MALDI: the cluster ionization mechanism. Chem. Rev. 2003, 103:427-440.
32. Leissring M.A., Lu A., Condron M.M., Teplow D.B., Stein R.L., Farris W., Selkoe D.J. Kinetics of amyloid beta-protein degradation determined by novel fluorescence- and fluorescence polarization-based assays. J.Biol. Chem. 2003, 278:37314-37320.
33. Mattsson N., Rajendran L., Zetterberg H., Gustavsson M., Andreasson U., Brinkmalm G., Lundkvist J., Jacobson L.H., Perrot L., Neumann U., Borghys, Mercken M., Dhuyvetter D., Jeppsson F., Blennow K., Portelius E. BACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous system. PLoS ONE 2012, 7:1-11.
34. Nalivaeva N.N., Beckett C., Belyaev N.D., Turner A.J. Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer's disease?. J.Neurochem. 2011, 120:167-185.
35. Nelson P.T., Braak H., Markesbery W.R. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J.Neuropathol. Exp. Neurol. 2009, 68:1-14.
36. Nilsson T., Mann M., Aebersold R., Yates J.R., Bairoch A., Bergeron J.J. Mass spectrometry in high-throughput proteomics: ready for the big time. Nat. Methods 2010, 7:681-685.
37. Pesini P., Monleón I., Pérez-Grijalba V., Lacosta A.M., Santamarina G., Suárez M.L., González-Martínez A., Boada M., Tárraga L., Sarasa M. The use of a C-terminal peptides in the early diagnosis and preventive treatment of AD. Neurobiol. Aging 2010, 31(S1):24.
38. Portelius E., Brinkmalm G., Tran A.J., Zetterberg H., Westman-Brinkmalm A., Blennow K. Identification of novel APP/Abeta isoforms in human cerebrospinal fluid. Neurodegener. Dis. 2009, 6:87-94.
39. Portelius E., Tran A.J., Andreasson U., Persson R., Brinkmalm G., Zetterberg H., Blennow K., Westman-Brinkmalm A. Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J.Proteome Res. 2007, 6:4433-4439.
40. Portelius E., Van Broeck B., Andreasson U., Gustavsson M.K., Mercken M., Zetterberg H., Borghys H., Blennow K. Acute effect on th Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs. J.Alzheimers Dis. 2010, 21:1005-1012.
41. Portelius E., Westman-Brinkmalm A., Zetterberg H., Blennow K. Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J.Proteome Res. 2006, 5:1010-1016.
42. Sarasa M., Pesini P. Natural non-trasgenic animal models for research in Alzheimer disease. Curr. Alzheimer Res. 2009, 6:171-178.
43. Sarasa L., Gallego C., Monleon I., Olvera A., Canudas J., Montanes M., Pesini P., Sarasa M. Cloning, sequencing and expression in the dog of the main amyloid precursor protein isoforms and some of the enzymes related with their processing. Neuroscience 2010, 171:1091-1101.
44. Schupf N., Tang M.X., Fukuyama H., Manly J., Andrews H., Mehta P., Ravetch J., Mayeux R. Peripheral Ab subspecies as risk biomarkers of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A 2008, 105:14052-14057.
45. Spengler B., Chaurand P., Bold P. MALDI Postsource Decay Mass Analysis 1999, Wiley-VCH Verlag, Weinhein, Germany.
46. Sun X., He G., Song W. BACE2, as novel APP θ-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome. FASEB J. 2006, 20:1369-1376.
47. Thambisetty M., Simmons A., Velayudhan L., Hye A., Campbell J., Zhang Y., Wahlund L.O., Westman E., Kinsey A., Guntert A., Proitsi P., Powell J., Causevic M., Killick R., Lunnon K., Lynham S., Broadstock M., Choudhry F., Howlett D.R., Williams R.J., Sharp S.I., Mitchelmore C., Tunnard C., Leung R., Foy C., O'Brien D., Breen G., Furney S.J., Ward M., Kloszewska I., Mecocci P., Soininen H., Tsolaki M., Vellas B., Hodges A., Murphy D.G., Parkins S., Richardson J.C., Resnick S.M., Ferrucci L., Wong D.F., Zhou Y., Muehlboeck S., Evans A., Francis P.T., Spenger C., Lovestone S. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch. Gen. Psychiatry 2010, 67:739-748.
48. Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., Teplow D.B., Ross S., Amarante P., Loeloff R., Luo Y., Fisher S., Fuller J., Edenson S., Lile J., Jarosinski M.A., Biere A.L., Curran E., Burgess T., Louis J.C., Collins F., Treanor J., Rogers G., Citron M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286:735-741.
49. Wiltfang J., Esselmann H., Bibl M., Smirnov A., Otto M., Paul S., Schmidt B., Klafki H.W., Maler M., Dyrks T., Bienert M., Beyermann M., Ruther E., Kornhuber J. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J.Neurochem. 2002, 81:481-496.